| Literature DB >> 28649252 |
Nur Ramziahrazanah Jumat1, Mun Yee Chong1, Zainina Seman2, Rosita Jamaluddin3, Nyet Kui Wong4, Maha Abdullah1.
Abstract
Sexual dimorphism in immune response is widely recognized, but few human studies have observed this distinction. Food with endo-immunomodulatory potential may reveal novel sex-biased in vivo interactions. Immunomodulatory effects of Carica papaya were compared between healthy male and female individuals. Volunteers were given fixed meals supplemented with papaya for 2 days. Changes in blood immune profiles and hormone levels were determined. In females, total natural killer (NK) cell percentages decreased (12.7 ± 4.4 vs 14.6 ± 5.8%, p = 0.018, n = 18) while B cells increased (15.2 ± 5.5 vs 14.5 ± 5.0, p = 0.037, n = 18) after papaya consumption. Increased 17β-estradiol (511.1 ± 579.7 vs 282.7 ± 165.0 pmol/l, p = 0.036, n = 9) observed in females may be crucial to this change. Differentiation markers (CD45RA, CD69, CD25) analyzed on lymphocytes showed naïve (CD45RA+) non-CD4+ lymphocytes were reduced in females (40.7 ± 8.1 vs 46.8 ± 5.4%, p = 0.012, n = 8) but not males. A general suppressive effect of papaya on CD69+ cells, and higher percentage of CD69+ populations in females and non-CD4 lymphocytes, may be relevant. CD107a+ NK cells were significantly increased in males (16.8 ± 7.0 vs 14.7 ± 4.8, p = 0.038, n = 9) but not females. Effect in females may be disrupted by the action of progesterone, which was significantly correlated with this population (R = 0.771, p = 0.025, n = 8) after papaya consumption. In males, total T helper cells were increased (33.4 ± 6.4 vs 32.4 ± 6.1%, p = 0.040, n = 15). Strong significant negative correlation between testosterone and CD25+CD4+ lymphocytes, may play a role in the lower total CD4+ T cells reported in males. Thus, dissimilar immune profiles were elicited in the sexes after papaya consumption and may have sex hormone influence.Entities:
Keywords: CD107a; CD25; CD69; Carica papaya; T cells; natural killer cells; sex hormones
Year: 2017 PMID: 28649252 PMCID: PMC5465248 DOI: 10.3389/fimmu.2017.00680
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Mean ± SD values of sex hormones and immune parameters in healthy males and females, combined (all samples) and pre- and post-papaya consumption.
| Pre-papaya vs post-papaya | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All samples | All subjects | Male | Female | All | M | F | |||||||||||
| Male | Female | M vs F | Pre- | Post- | Pre- | Post- | Pre- | Post- | (Pre- vs Post-) | ||||||||
| Estradiol (pmol/l) | 98.1 ± 26.5 | 18 | 396.9 ± 429.9 | 18 | 191.5 ± 147.9 | 303.5 ± 451.9 | 18 | 100.3 ± 23.9 | 95.8 ± 30.1 | 9 | 282.7 ± 165.0 | 511.1 ± 579.7 | 9 | ||||
| Progesterone (nmol/l) | 18 | 6.4 ± 9.7 | 18 | 2.8 ± 6.8 | 4.0 ± 8.1 | 18 | 0.3 ± 0.0 | 0.3 ± 0.0 | 9 | 5.2 ± 9.2 | 7.61 ± 0.5 | 9 | |||||
| Testosterone (nmol/l) | 7.5 ± 2.5 | 18 | 0.8 ± 0.5 | 18 | 4.3 ± 4.0 | 4.0 ± 3.8 | 18 | 7.8 ± 2.5 | 7.2 ± 2.7 | 9 | 0.8 ± 0.4 | 0.8 ± 0.7 | 9 | ||||
| CD3+CD4+ % | 32.9 ± 6.1 | 30 | 37.1 ± 8.9 | 36 | 34.8 ± 8.3 | 35.6 ± 7.8 | 33 | 32.4 ± 6.1 | 33.4 ± 6.4 | 15 | 36.8 ± 9.4 | 37.5 ± 8.5 | 18 | ||||
| CD3+CD4+ cnt | 858.5 ± 264.2 | 30 | 980.1 ± 543.2 | 36 | 927.6 ± 485.2 | 922.0 ± 397.6 | 33 | 857 ± 254.6 | 860.0 ± 282.5 | 15 | 986.4 ± 617.8 | 973.7 ± 475.0 | 18 | ||||
| CD3+CD8+ % | 28.1 ± 9.1 | 30 | 28.7 ± 6.7 | 36 | 28.4 ± 8.0 | 28.5 ± 7.7 | 33 | 28.3 ± 9.3 | 28.0 ± 9.1 | 15 | 28.5 ± 7.0 | 29.0 ± 6.6 | 18 | ||||
| CD3+CD8+ cnt | 748.4 ± 352.0 | 30 | 719.0 ± 295.1 | 36 | 741.2 ± 345.0 | 723.6 ± 297.9 | 33 | 766.8 ± 372.7 | 730.1 ± 342.0 | 15 | 719.8 ± 329.6 | 718.2 ± 265.8 | 18 | ||||
| CD3−CD16+ 56% | 16.8 ± 5.9 | 30 | 13.6 ± 5.2 | 36 | 15.7 ± 6.0 | 14.4 ± 5.5 | 33 | 17.1 ± 6.0 | 16.4 ± 6.1 | 15 | 14.6 ± 5.8 | 12.7 ± 4.4 | 18 | ||||
| CD3−CD16+56 cnt | 465.3 ± 274.9 | 30 | 343.5 ± 202.5 | 36 | 413.2 ± 245.1 | 384.5 ± 245.9 | 33 | 474.6 ± 264.9 | 456.1 ± 293.5 | 15 | 362.1 ± 221.7 | 324.8 ± 185.9 | 18 | ||||
| CD3−CD19+ % | 13.6 ± 3.5 | 30 | 14.9 ± 5.2 | 36 | 14.1 ± 4.4 | 14.4 ± 4.7 | 33 | 13.7 ± 3.8 | 13.5 ± 3.4 | 15 | 14.5 ± 5.0 | 15.2 ± 5.5 | 18 | ||||
| CD3−CD19+ cnt | 362.8 ± 151.7 | 30 | 373.1 ± 199.3 | 36 | 370.0 ± 194.3 | 366.8 ± 163.1 | 33 | 371.4 ± 153.7 | 354.2 ± 154.7 | 15 | 368.9 ± 227.1 | 377.4 ± 173.6 | 18 | ||||
| CD4+CD45RA+ | 14.3 ± 4.3 | 16 | 16.2 ± 6.4 | 16 | 15.6 ± 5.4 | 15.0 ± 5.7 | 16 | 14.9 ± 5.1 | 13.8 ± 3.5 | 8 | 16.3 ± 5.8 | 16.2 ± 7.4 | 8 | ||||
| CD69−CD25− | 52.5 ± 12.6 | 16 | 53.1 ± 12.5 | 16 | 52.5 ± 11.8 | 53.1 ± 13.3 | 16 | 51.6 ± 11.9 | 53.5 ± 14.0 | 8 | 53.4 ± 12.3 | 52.7 ± 13.4 | 8 | ||||
| CD69−CD25+ | 42.7 ± 13.6 | 16 | 40.3 ± 13.0 | 16 | 41.4 ± 12.5 | 41.6 ± 14.1 | 16 | 43.4 ± 13.2 | 42.1 ± 14.8 | 8 | 39.3 ± 12.4 | 41.2 ± 14.4 | 8 | ||||
| CD69+CD25− | 2.8 ± 2.5 | 16 | 4.0 ± 3.5 | 16 | 3.7 ± 3.5 | 3.0 ± 2.6 | 16 | 3.0 ± 2.8 | 2.6 ± 2.2 | 8 | 4.5 ± 4.1 | 3.5 ± 3.0 | 8 | ||||
| CD69+CD25+ | 2.0 ± 2.0 | 16 | 2.7 ± 2.1 | 16 | 2.5 ± 2.1 | 2.2 ± 2.0 | 16 | 2.1 ± 2.1 | 1.9 ± 2.0 | 8 | 2.9 ± 2.2 | 2.6 ± 2.2 | 8 | ||||
| CD4+CD45RA− | 13.9 ± 3.0 | 16 | 16.3 ± 4.8 | 16 | 15.3 ± 4.1 | 14.9 ± 4.2 | 16 | 13.9 ± 2.7 | 14.0 ± 3.4 | 8 | 16.7 ± 4.9 | 15.9 ± 5.0 | 8 | ||||
| CD69−CD25− | 46.9 ± 12.2 | 16 | 46.3 ± 12.3 | 16 | 46.1 ± 11.4 | 47.0 ± 13.1 | 16 | 45.8 ± 11.6 | 48.0 ± 13.5 | 8 | 46.5 ± 11.9 | 46.1 ± 13.5 | 8 | ||||
| CD69−CD25+ | 51.8 ± 12.3 | 16 | 51.6 ± 12.4 | 16 | 52.0 ± 11.6 | 51.4 ± 13.1 | 16 | 52.8 ± 11.8 | 50.8 ± 13.5 | 8 | 51.2 ± 12.1 | 52.0 ± 13.5 | 8 | ||||
| CD69+CD25− | 0.6 ± 0.3 | 16 | 0.9 ± 0.8 | 16 | 0.8 ± 0.7 | 0.6 ± 0.6 | 16 | 0.6 ± 0.3 | 0.5 ± 0.3 | 8 | 1.1 ± 0.8 | 0.8 ± 0.9 | 8 | ||||
| CD69+CD25+ | 0.7 ± 0.3 | 16 | 1.2 ± 1.0 | 16 | 1.0 ± 0.8 | 0.9 ± 0.8 | 16 | 0.8 ± 0.4 | 0.7 ± 0.3 | 8 | 1.3 ± 1.0 | 1.1 ± 1.0 | 8 | ||||
| CD4−CD45RA+ | 47.6 ± 5.4 | 16 | 43.7 ± 7.3 | 16 | 47.5 ± 5.1 | 43.9 ± 7.6 | 16 | 48.2 ± 5.1 | 47.1 ± 5.9 | 8 | 46.8 ± 5.4 | 40.7 ± 8.1 | 8 | ||||
| CD69−CD25− | 91.4 ± 7.2 | 16 | 90.4 ± 7.0 | 16 | 90.2 ± 7.7 | 91.6 ± 6.3 | 16 | 90.7 ± 8.3 | 92.2 ± 6.4 | 8 | 89.7 ± 7.6 | 91.1 ± 6.7 | 8 | ||||
| CD69+CD25− | 8.0 ± 7.0 | 16 | 9.1 ± 7.1 | 16 | 9.3 ± 7.7 | 7.8 ± 6.4 | 16 | 8.8 ± 8.0 | 7.2 ± 6.3 | 8 | 9.8 ± 7.9 | 8.3 ± 6.8 | 8 | ||||
| CD4−CD45RA− | 24.1 ± 5.6 | 16 | 23.8 ± 10.3 | 16 | 21.7 ± 5.7 | 26.2 ± 9.7 | 16 | 23.0 ± 5.6 | 25.2 ± 5.8 | 8 | 20.3 ± 5.8 | 27.3 ± 12.8 | 8 | ||||
| CD69−CD25− | 93.5 ± 2.1 | 16 | 89.0 ± 9.5 | 16 | 91.2 ± 6.2 | 91.3 ± 8.2 | 16 | 93.3 ± 2.0 | 93.7 ± 2.3 | 8 | 89.1 ± 8.2 | 88.9 ± 11.2 | 8 | ||||
| CD69+CD25− | 5.3 ± 2.3 | 16 | 10.4 ± 9.4 | 16 | 7.7 ± 6.4 | 8.0 ± 8.2 | 16 | 5.2 ± 2.4 | 5.5 ± 2.4 | 8 | 10.3 ± 8.2 | 10.6 ± 11.1 | 8 | ||||
| CD8+ cytotoxic T cells | |||||||||||||||||
| CD3+CD8+IFN+ | 6.0 ± 4.8 | 16 | 7.1 ± 5.7 | 16 | 7.0 ± 5.4 | 6.1 ± 5.0 | 16 | 6.7 ± 5.7 | 5.3 ± 3.8 | 8 | 7.2 ± 5.5 | 7.0 ± 6.2 | 8 | ||||
| CD3+CD8+IL-12R+ | 4.6 ± 1.7 | 16 | 5.4 ± 2.2 | 16 | 5.0 ± 2.1 | 5.0 ± 2.0 | 16 | 4.7 ± 2.0 | 4.6 ± 1.5 | 8 | 5.2 ± 2.3 | 5.5 ± 2.3 | 8 | ||||
| CD3+CD8+IL-15R+ | 8.4 ± 4.5 | 18 | 9.6 ± 5.3 | 16 | 9.5 ± 4.9 | 8.4 ± 4.9 | 17 | 8.6 ± 4.5 | 8.2 ± 4.7 | 9 | 10.5 ± 5.4 | 8.7 ± 5.4 | 8 | ||||
| CD3+CD8+IL-21R+ | 7.2 ± 2.8 | 16 | 8.6 ± 3.6 | 16 | 8.1 ± 3.5 | 7.7 ± 3.0 | 16 | 7.1 ± 3.5 | 7.2 ± 2.1 | 8 | 9.0 ± 3.5 | 8.2 ± 3.8 | 8 | ||||
| CD3+CD8+CD107a+ | 5.8 ± 2.3 | 18 | 5.3 ± 1.8 | 16 | 5.7 ± 2.0 | 5.5 ± 2.2 | 18 | 6.0 ± 2.1 | 5.6 ± 2.7 | 9 | 5.3 ± 2.0 | 5.3 ± 1.8 | 9 | ||||
| CD3−CD56+IFN+ | 21.1 ± 2.1 | 14 | 23.1 ± 15.7 | 14 | 21.9 ± 14.5 | 22.2 ± 13.5 | 14 | 22.6 ± 13.4 | 19.5 ± 11.5 | 7 | 21.3 ± 16.7 | 24.9 ± 15.7 | 7 | ||||
| CD3−CD56+IL12R+ | 11.2 ± 5.3 | 16 | 13.2 ± 6.5 | 16 | 11.9 ± 5.7 | 12.5 ± 6.3 | 16 | 11.0 ± 5.3 | 11.5 ± 5.7 | 8 | 12.8 ± 6.2 | 13.5 ± 7.2 | 8 | ||||
| CD3−CD56+IL15R+ | 17.9 ± 11.5 | 18 | 20.0 ± 9.9 | 18 | 20.3 ± 12.9 | 17.6 ± 7.7 | 18 | 18.4 ± 14.8 | 17.3 ± 7.6 | 9 | 22.1 ± 11.3 | 17.8 ± 8.3 | 9 | ||||
| CD3−CD56+IL-21R+ | 17.8 ± 6.9 | 16 | 21.7 ± 10.2 | 16 | 20.1 ± 8.5 | 19.3 ± 9.4 | 16 | 16.9 ± 5.8 | 18.6 ± 8.2 | 8 | 23.4 ± 9.8 | 20.0 ± 11.0 | 8 | ||||
| CD3−CD56+CD107a+ | 15.7 ± 5.9 | 18 | 16.1 ± 6.9 | 16 | 15.1 ± 6.5 | 16.7 ± 6.2 | 17 | 14.7 ± 4.8 | 16.8 ± 7.0 | 9 | 15.6 ± 8.4 | 16.5 ± 5.7 | 8 | ||||
M, male; F, female; n, number of samples.
Statistical significance achieved where p < 0.05.
Figure 1Distribution of sex hormone levels in healthy human males (N = 9) and females (N = 9), pre- and post-papaya consumption. (A) 17β-estradiol, (B) progesterone, and (C) testosterone. *Statistical significance achieved where p < 0.05.
Figure 2Distribution of (A) total CD3−CD56+ NK cells, (B) total CD3−CD19+ B cells, and (C) total CD3+CD4+ helper T cells percentages in healthy males (n = 15) and females (n = 18) pre- and post-papaya consumption. *Statistical significance achieved where p < 0.05.
Figure 3(A) Flow cytometry gating strategy for analysis of differentiation markers expressed on CD4+ T cells/non-CD4+ lymphocytes in lysed whole blood. Initial gating was on lymphocytes with low SSC/low FSC. Distribution of (B) CD69+ in CD4+ T cell subpopulations i. naïve, CD4+CD45RA+CD69+CD25− and ii. activated, CD4+CD45RA−CD69+CD25−, and (C) non-CD4+ lymphocytes i. total naïve CD4+CD45RA+ and ii. total activated CD4+CD45RA− in healthy males (n = 8) and females (n = 8) pre- and post-papaya consumption. (D) Representative flow cytometry plots showing CD69+ fractions in naïve, CD45RA+ and activated CD45RA− CD4+ T cells and non-CD4+ lymphocytes. *Statistical significance achieved where p < 0.05.
Figure 4(A) Flow cytometry gating strategy to analyze degranulation marker, CD107a on CD3+CD8+ cytotoxic T cells and CD3−CD56+ NK cells. Initial gating was on lymphocytes with low SSC/low FSC (B) distribution of CD107a NK cell percentages in healthy male (n = 9) and females (n = 8) pre- and post-papaya consumption. *Statistical significance achieved where p < 0.05.